134 related articles for article (PubMed ID: 9875670)
1. Genetic immunization against neu/erbB2 transgenic breast cancer.
Amici A; Venanzi FM; Concetti A
Cancer Immunol Immunother; 1998 Dec; 47(4):183-90. PubMed ID: 9875670
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
3. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
4. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
Esserman LJ; Lopez T; Montes R; Bald LN; Fendly BM; Campbell MJ
Cancer Immunol Immunother; 1999 Feb; 47(6):337-42. PubMed ID: 10203064
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
[TBL] [Abstract][Full Text] [Related]
10. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA.
Concetti A; Amici A; Petrelli C; Tibaldi A; Provinciali M; Venanzi FM
Cancer Immunol Immunother; 1996 Dec; 43(5):307-15. PubMed ID: 9024508
[TBL] [Abstract][Full Text] [Related]
12. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
13. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
14. Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.
Provinciali M; Barucca A; Orlando F; Pierpaoli E
Sci Rep; 2017 Jun; 7(1):3078. PubMed ID: 28596550
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Amici A; Smorlesi A; Noce G; Santoni G; Cappelletti P; Capparuccia L; Coppari R; Lucciarini R; Petrelli C; Provinciali M
Gene Ther; 2000 Apr; 7(8):703-6. PubMed ID: 10800094
[TBL] [Abstract][Full Text] [Related]
16. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
Saha A; Chatterjee SK
Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
[TBL] [Abstract][Full Text] [Related]
18. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.
Quaglino E; Mastini C; Forni G; Cavallo F
Curr Protoc Immunol; 2008 Aug; Chapter 20():Unit 20.9.1-20.9-10. PubMed ID: 18729063
[TBL] [Abstract][Full Text] [Related]
20. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
Wang QF; Ding H; Liu BR; Zhang K
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
